Eptifibatide Injection

• • Integrilin injection, Merck, 2 mg/mL, 100 mL vial, 1 count, NDC 00085-1177-02
  • Eptifibatide injection, Akorn, 0.75 mg/mL, 100 mL vial, 1 count, NDC 17478-0903-90
  • Eptifibatide injection, Akorn, 2 mg/mL, 10 mL vial, 1 count, NDC 17478-0902-10
  • Eptifibatide injection, Amneal, 0.75 mg/mL, 100 mL vial, 1 count, NDC 70121-1003-01
  • Eptifibatide injection, Amneal, 2 mg/mL, 10 mL vial, 1 count, NDC 70121-1002-01
  • Eptifibatide injection, AuroMedics, 0.75 mg/mL, 100 mL vial, 1 count, NDC 55150-0218-99
  • Eptifibatide injection, AuroMedics, 2 mg/mL, 100 mL vial, 1 count, NDC 55150-0220-99
  • Eptifibatide injection, Sagent, 0.75 mg/mL, 100 mL vial, 1 count, NDC 25021-0408-51
  • Eptifibatide injection, Sagent, 2 mg/mL, 10 mL vial, 1 count, NDC 25021-0409-10

• • Accord has temporarily discontinued eptifibatide injection.
  • Akorn did not provide a reason for the shortage.
  • Amneal did not provide a reason for the shortage.
  • Auromedics did not provide a reason for the shortage.
  • Baxter has eptifibatide injection available.
  • Merck did not provide a reason for the shortage.
  • Mylan has eptifibatide injection available.
  • Sagent states the shortage is due to manufacturing delay.
  • Slate Run has eptifibatide injection available.

• • Integrilin injection, Merck, 0.75 mg/mL, 100 mL vial, 1 count, NDC 00085-1136-01
  • Integrilin injection, Merck, 2 mg/mL, 10 mL vial, 1 count, NDC 00085-1177-01
  • Eptifibatide injection, AuroMedics, 2 mg/mL, 10 mL vial, 1 count, NDC 55150-0219-10
  • Eptifibatide injection, Baxter, 0.75 mg/mL, 100 mL vial, 1 count, NDC 00338-9558-10
  • Eptifibatide injection, Mylan Institutional, 0.75 mg/mL, 100 mL vial, 1 count, NDC 67457-0631-10
  • Eptifibatide injection, Mylan Institutional, 2 mg/mL, 10 mL vial, 1 count, NDC 67457-0629-10
  • Eptifibatide injection, Mylan Institutional, 2 mg/mL, 100 mL vial, 1 count, NDC 67457-0630-10
  • Eptifibatide injection, Slate Run Pharmaceuticals, 0.75 mg/mL, 100 mL vial, 1 count, NDC 70436-0027-80
  • Eptifibatide injection, Slate Run Pharmaceuticals, 2 mg/mL, 10 mL vial, 1 count, NDC 70436-0026-80

Estimated Resupply Dates

• • Akorn has eptifibatide 0.75 mg/mL in 100 mL vials and 2 mg/mL in 10 mL vials on back order and the company estimates a release date in mid-June 2020.
  • Amneal has eptifibatide 0.75 mg/mL in 100 mL vials and 2 mg/mL in 10 mL vials on back order and the company cannot estimate a release date.
  • Auromedics has eptifibatide 0.75 mg/mL and 2 mg/mL in 100 mL vials on intermittent back order and the company is releasing product as it becomes available.
  • Merck has Integrilin 2 mg/mL in 100 mL vials on back order and the company cannot estimate a release date.
  • Sagent has eptifibatide 0.75 mg/mL in 100 mL vials and 2 mg/mL in 10 mL vials on back order and the company estimates release dates in June 2020.